An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new roundup looked at the evidence comparing different GLP-1 drugs — the kind people hear about for weight loss, like Ozempic and Wegovy — to see which one seems best right now. The piece reviews the studies we have and tries to sort out which medicines lead to the biggest weight loss and what trade-offs exist. It’s not announcing a single “winner” so much as summarizing where the data stands for 2025–2026. GLP-1 drugs are medicines that mimic a hormone your gut normally makes after you eat. That hormone tells your brain you’re full and slows how fast your stomach empties, so you eat less and feel satisfied longer. Semaglutide and tirzepatide are two of the best-known ones. Some are approved specifically for diabetes, others for weight loss; they come as injected medicines given weekly in most cases. What the reviews and studies show so far is that several of these drugs can lead to substantial weight loss compared with placebo (a dummy treatment). Trials for tirzepatide and higher-dose semaglutide reported some of the largest average weight losses — often in the range of 15–20% of body weight over many months in clinical trials. But those are controlled studies with select groups of people, and results vary: some people lose less, some lose more. Head-to-head trials are limited, so much of the comparison relies on separate studies that used different methods and populations. That makes direct comparisons imperfect. Why this matters is practical. If you or someone you know is considering medical help for obesity, the evidence suggests some GLP-1–type drugs can produce large, clinically meaningful weight loss and improve health measures like blood sugar. That can change decisions about treatment for people with obesity or type 2 diabetes, and it influences what doctors might recommend and what insurers might cover. It also affects how pharmaceutical companies price and position their drugs. There are important caveats and risks. These drugs commonly cause nausea, diarrhea, and stomach issues, especially when doses are increased. Long-term safety beyond a few years is still being studied. Stopping the drug often leads to weight regain unless other lifestyle or medical measures are in place. Not everyone is eligible or should use these medicines; they need a prescription and medical monitoring, and they may interact with other conditions or drugs. Regulatory approvals and recommended doses differ between countries and between diabetes versus weight-loss indications. Bottom line: Multiple GLP-1–class drugs look effective for weight loss, and some newer options appear more potent than older ones, but comparisons aren’t definitive and decisions should be individualized with a clinician.
Source: BusinessWorld Online